Clinical trials: Generalized Lipodystrophy
Hypoleptinemia, Generalized Lipodystrophy
Trial of Leptin Replacement Therapy in Patients With Lipodystrophy
Lipodystrophies represent a therapeutic challenge with regards to insulin resistance, hypertriglyceridemia and fatty liver which often is coupled with significant adipose tissue loss.
- Conditions
- Hypoleptinemia, Generalized Lipodystrophy, Partial Lipodystrophy, Insulin Resistance
- Trial name
- NCT00896298
- Testing
- Leptin
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Texas Southwestern Medical Center
Generalized Lipodystrophy
Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy
MYALEPT™ (metreleptin) has been approved as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy (MYALEPT Prescribing…
- Trial name
- NCT04026178
- Testing
- Metreleptin
- Where
- 8 sites in United States
- Volunteers
- 11 people
- Sponsor
- Aegerion Pharmaceuticals, Inc.
Eye Manifestations
Ocular Surface Changes in Patients With Cystic Fibrosis
Cystic fibrosis(CF) is an inherited disease affecting children, adolescents and young adults with dysfunction of secretory glands.It is caused by mutations in the protein-coding gene which function as the cystic fibrosis…
- Trial name
- NCT00345280
- Testing
- impression cytology, obtain the tear fluid
- Where
- Poland
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of Bialystok
PET/CT, Solid Tumors, Adult
Granzyme B-targeted PET Imaging Monitoring Tumor Responses to Immunotherapy
Malignant solid tumors, characterized by their persistently high incidence and mortality rates, pose a significant threat to human health and life, imposing a substantial societal burden.
- Conditions
- PET/CT, Solid Tumors, Adult, Solid Tumors, Advanced Solid Tumors
- Trial name
- GZMB_PET (NCT06916442)
- Testing
- PET/CT Imaging with GZMB-targeted tracer
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Zhongnan Hospital
Chronic Right-Sided Heart Failure, Pulmonary Arterial Hypertension
Spironolactone Therapy in Chronic Stable Right HF Trial
The purpose of this study is to evaluate the safety, tolerability and mechanistic effects of spironolactone, an aldosterone receptor antagonist, on sympathetic nervous system activity and right heart function and remodeling in…
- Conditions
- Chronic Right-Sided Heart Failure, Pulmonary Arterial Hypertension, Pulmonary Hypertension, Primary, 2, Pulmonary Hypertension, Primary, 3
- Trial name
- STAR-HF (NCT03344159)
- Testing
- Spironolactone, PET/CT Scan: Two PET scans using 1. C-11 HED and 2. N-13 Ammonia or rubidium-82, Cardiac MRI (Gadolinium enhanced)
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Cancer
68Ga-grazytracer PET/CT of Tumor Responses to Immunotherapy
This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the safety and clinical predictive value of 68Ga-grazytracer in subjects with solid tumor or lymphoma receiving immunotherapy.
- Trial name
- NCT05000372
- Testing
- 68Ga-grazytracer
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Peking University Cancer Hospital & Institute
Breast Cancer Invasive
GzmB-PET/CT to Evaluate Neoadjuvant Therapy Efficacy in Breast Cancer
To explore the efficacy of 68Ga-GZMB PET/CT in assessing the response to neoadjuvant therapy for breast cancer, and to investigate the optimal SUVmax threshold of 68Ga-GZMB PET/CT for predicting pathological complete response…
- Trial name
- GzmB-PET4BC (NCT06725940)
- Testing
- 68Ga-GZMB PET/CT
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Generalized Lipodystrophy
Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy
The primary objectives of the study are to estimate the effects of REGN4461 on glycemic parameters in the subset of patients with elevated baseline hemoglobin A1c levels (HbA1c ≥7%) and to estimate the effects of REGN4461 on…
- Trial name
- NCT04159415
- Testing
- Low-Dose REGN4461, High-dose REGN4461
- Where
- 8 sites in United States, Peru and 2 more
- Volunteers
- 16 people
- Sponsor
- Regeneron Pharmaceuticals